Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Каталог · ЕАЭС

Клинические исследования и проекты

Boehringer Ingelheim · найдено 84

Boehringer Ingelheim
Ищем по всем вариантам написания в реестрах, по-русски и по-английски. Спонсор или разработчик.
Статус
Что исследуют
Источник
Фаза
Страна
Участники
Кто может участвовать По критериям ClinicalTrials.gov. Исследования, где реестр возраст и пол не указывает, тоже показываются. Возраст и пол нигде не сохраняются.
Сбросить
84 исследования
Идёт Фаза III Казахстан
Tenecteplase; Standard of care treatment · Boehringer Ingelheim

TENACITY - A Phase III, Prospective, Randomized, Open-label, Blinded Endpoint Assessment (PROBE) to Assess Efficacy and Safety of i.v. Tenecteplase vs Standard of Care in Patients With Acute Ischemic Stroke (Including Wake-up Stroke), Last Known Well >4.5 h With Imaging Evidence of Salvageable Ischemic Tissue

Астана 2 центра 1 325 участников во всех странах ClinicalTrials.gov 1123-0060
Идёт Фаза III Казахстан
verducatib · Boehringer Ingelheim

An Open-label, Roll-over Study Evaluating the Long-term Safety and Efficacy of an Oral Dose of Verducatib q.d. in Patients With Bronchiectasis (AIRTIVITY®-ON)

Астана, Караганда 2 центра 1 500 участников во всех странах ClinicalTrials.gov 1397-0018
Завершено Казахстан
248.675 · Boehringer Ingelheim

Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice

1 814 участников во всех странах ClinicalTrials.gov 248.675
Идёт Фаза III Казахстан
1404-0044 · Boehringer Ingelheim

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis

Алматы 2 центра 1 800 участников во всех странах ClinicalTrials.gov 1404-0044
Идёт Фаза III Казахстан
BI 1291583; Placebo matching BI 1291583 · Boehringer Ingelheim

A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)

Астана, Караганда 2 центра 1 755 участников во всех странах ClinicalTrials.gov 1397-0014
Завершено Фаза III Россия
Placebo; tiotropium Respimat® low dose; Placebo; Placebo; tiotropium Respimat® high dose; 50 mcg salmeterol HFA MDI; Placebo; Placebo · Boehringer Ingelheim

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma

1 071 участник во всех странах ClinicalTrials.gov 205.418
Завершено Фаза III Россия
tiotropium 18 mcg; tiotropium 1.25 mcg (2 actuations/day); tiotropium 2.5 mcg (2 actuations/day) · Boehringer Ingelheim

A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)

17 183 участника во всех странах ClinicalTrials.gov 205.452
Завершено Фаза III Россия
Pramipexol Extended Release; Pramipexol Immediate Release; Placebo · Boehringer Ingelheim

A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).

539 участников во всех странах ClinicalTrials.gov 248.524
Завершено Фаза III Россия
warfarin; Dabigatran dose 1; Dabigatran dose 2 · Boehringer Ingelheim

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)

18 113 участников во всех странах ClinicalTrials.gov 1160.26
Завершено Фаза III Россия
Pemetrexed; BIBW 2992; Cisplatin · Boehringer Ingelheim

A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation

Москва, Санкт-Петербург и ещё 2 города 6 центров 345 участников во всех странах ClinicalTrials.gov 1200.32
Завершено Фаза III Россия
telmisartan; simvastatin · Boehringer Ingelheim

Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia

1 695 участников во всех странах ClinicalTrials.gov 1228.1
Завершено Фаза IV Россия
Pramipexole · Boehringer Ingelheim

A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms

296 участников во всех странах ClinicalTrials.gov 248.596
Завершено Фаза III Россия
amlodipine; telmisartan; telmisartan and amlodipine · Boehringer Ingelheim

An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg & Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3).

858 участников во всех странах ClinicalTrials.gov 1235.20
Завершено Фаза III Россия
dabigatran etexilate 150 mg; warfarin (INR 2-3) · Boehringer Ingelheim

A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication.

2 564 участника во всех странах ClinicalTrials.gov 1160.53
Завершено Россия
205.450 · Boehringer Ingelheim

Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region

4 852 участника во всех странах ClinicalTrials.gov 205.450
Завершено Россия
1237.44 · Boehringer Ingelheim

Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice.

7 443 участника во всех странах ClinicalTrials.gov 1237.44
Завершено Фаза III Россия
Linagliptin; Linagliptin Placebo; Glimepiride · Boehringer Ingelheim

A Randomised, db, Placebo-controlled, Parallel Group Efficacy and Safety Study of BI 1356 (5mg), Administered Orally Once Daily for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients With Insufficient Glycaemic Control for Whom Metformin Therapy is Inappropriate (Intolerability or Contraindication)

227 участников во всех странах ClinicalTrials.gov 1218.50
Завершено Фаза IV Россия
Aggrenox; Aggrenox; Clopidogrel placebo; Clopidogrel placebo; Micardis; Micardis; Aggrenox placebo; Aggrenox placebo; Clopidogrel; Clopidogrel; Micardis placebo; Micardis placebo · Boehringer Ingelheim

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis

20 332 участника во всех странах ClinicalTrials.gov 9.159
Завершено Фаза III Россия
Meloxicam · Boehringer Ingelheim

A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis

Москва 2 центра 1 000 участников во всех странах ClinicalTrials.gov 107.258
Завершено Фаза III Россия
nevirapine IR; nevirapine XR · Boehringer Ingelheim

A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada® in Antiretroviral Therapy naïve HIV-1 Infected Patients (VERxVE)

1 068 участников во всех странах ClinicalTrials.gov 1100.1486

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.